Raquel Izumi
- Genetics top 0.2%
- Pathology and Forensic Medicine top 0.5%
- Immunology top 5%
- Hematology top 1%
- Oncology top 5%
- Co-authors
- Ahmed HamdyRichard R. FurmanJeff P. SharmanNathan FowlerJoseph J. BuggyRanjana H. AdvaniBarbara GrantBetty Chang
- Topics
- Chronic Lymphocytic Leukemia Research (44 papers)Lymphoma Diagnosis and Treatment (28 papers)Advanced Breast Cancer Therapies (8 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Raquel Izumi
71 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Genetics 1.8k
- Pathology and Forensic Medicine 1.5k
- Immunology 644
- Hematology 638
- Oncology 580
Countries citing papers authored by Raquel Izumi
This map shows the geographic impact of Raquel Izumi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raquel Izumi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raquel Izumi more than expected).
Fields of papers citing papers by Raquel Izumi
This network shows the impact of papers produced by Raquel Izumi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raquel Izumi. The network helps show where Raquel Izumi may publish in the future.
Co-authorship network of co-authors of Raquel Izumi
This figure shows the co-authorship network connecting the top 25 collaborators of Raquel Izumi. A scholar is included among the top collaborators of Raquel Izumi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raquel Izumi. Raquel Izumi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 7 | |
| 4 | 8 | |
| 5 | 1 | |
| 6 | 30 | |
| 7 | 76 | |
| 8 | 40 | |
| 9 | 57 | |
| 10 | 21 | |
| 11 | 144 | |
| 12 | 25 | |
| 13 | 272 | |
| 14 | 121 | |
| 15 | 43 | |
| 16 | 8 | |
| 17 | Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignanciesbreakdown → | 848 |
| 18 | 25 | |
| 19 | 4 | |
| 20 | 74 |
About Raquel Izumi
Raquel Izumi is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology, having authored 72 papers that have together received 2.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (44 papers), Lymphoma Diagnosis and Treatment (28 papers) and Advanced Breast Cancer Therapies (8 papers). The work is most often cited by research in Genetics (1.8k citations), Pathology and Forensic Medicine (1.5k citations) and Hematology (638 citations). Raquel Izumi has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ahmed Hamdy, Richard R. Furman, Jeff P. Sharman, Nathan Fowler, Joseph J. Buggy, Ranjana H. Advani, Barbara Grant, Betty Chang, Thomas E. Boyd and Sonali M. Smith. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.